TB-500 dosage and half-life

Stroke experiment in rats

The Morris rat embolic-stroke study is the awkward entry in any simple more-means-better story. Full thymosin beta-4 was given intraperitoneally at 2, 12 or 18 milligrams per kilogram. Neurological function improved at 2 and 12 milligrams per kilogram, with significant effects from day 14 through day 56. At 18 milligrams per kilogram there was no significant benefit.

I prefer showing the tested amounts side by side to sketching a smooth rising curve. The paper reports a non-monotonic response: increasing the amount did not produce steadily increasing benefit. These are study amounts in rats after an induced stroke. They provide no human TB-500 regimen.

Human and mouse study amounts

In the human intravenous Phase 1 study of full thymosin beta-4, the tested amounts were 42, 140, 420, and 1260 milligrams. Testing included a single dose and daily administration for 14 days. Forty healthy volunteers participated. The paper reports infrequent mild or moderate adverse events and no dose-limiting toxicities or serious adverse events.

For the dystrophin-deficient mouse experiment, the amount was 150 micrograms intraperitoneally twice weekly for six months. The animals formed more regenerating fibers without significant improvements in strength or systolic cardiac function.

Putting those numbers into one ledger exposes how different the experiments were. Species, molecule, route, disease model and endpoint all change. A human fragment dose drawn from that mixture would require assumptions the studies never tested.

TB-500 half-life

Half-life is the time required for an amount in the body to fall by half. No validated human pharmacokinetic half-life is available here for the TB-500 heptapeptide. The Phase 1 pharmacokinetic result—how the body handled the substance—concerns full thymosin beta-4, whose half-life increased with dose.

Online loading and maintenance plans have no controlled human trial behind them. Subcutaneous and intramuscular use appears in anecdotal accounts, while the principal rodent studies used intraperitoneal administration and the human Phase 1 used a vein. No comparative human test establishes which route produces a particular TB-500 exposure. Guessing at that missing interval would be a poor use of my confidence.

TB-500 clearance and detection

How long does TB-500 stay in your system? This record supplies no validated human clearance time. The equine anti-doping analysis detected TB-500 and its metabolites, the pieces left as it breaks down, in horse plasma and urine. Liquid chromatography-mass spectrometry separates substances and identifies them by mass. It gives laboratories a way to look for exposure.

There is an imbalance here that bothers me: the fragment has a precise detection identity while a validated human clearance time remains unavailable. A laboratory’s ability to find a trace answers a different question from how long a substance acts in a person. Neither the horse assay nor the parent-protein trial supplies a human TB-500 clearance window.